Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasmiditan DDI with Dabigatran and Rosuvastatin
NCT04749914Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lasmiditan in migraine (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration of Dabigatran at 72 hours, Maximum Concentration of Rosuvastatin at 72 hours and 2 more. Started Feb 2021; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04749914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749914.